NCT03764488View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability, and Distribution of a Microdose of Radiolabeled BIIB067 (99mTc-MAG3-BIIB067) Co-administered With BIIB067 (Tofersen) to Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 20, 2018

Primary Completion Date

June 10, 2021

Study Completion Date

July 10, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

Tofersen

Administered as specified in the treatment arm.

DRUG

99mTc-MAG3-BIIB067

Administered as specified in the treatment arm.

Trial Locations (2)

10065

Research Site, New York

02114

Research Site, Boston

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT03764488 - A Study to Evaluate Safety, Tolerability, and Distribution of a Microdose of Radiolabeled BIIB067 (99mTc-MAG3-BIIB067) Co-administered With BIIB067 (Tofersen) to Healthy Adults | Biotech Hunter | Biotech Hunter